Kiora Pharmaceuticals (KPRX) AI Stock Analysis

• Market Cap: $8.83M
• Dividend Yield: N/A
• Average Volume (3M): 36.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -100.00%
• EPS Growth: -463.97%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 3,677,935
• 10 Day Avg. Volume: 38,148
• 30 Day Avg. Volume: 36,176
• PEG Ratio: -0.03
• Price to Book (P/B): 0.50
• Price to Sales (P/S): 0.80
• P/FCF Ratio: 1.49
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -97.35
• Enterprise Value/Ebitda: -0.51
• 1Y Price Target: $12.00
• Price Target Upside: 528.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.50 ▲(30.89% Upside)

The score is held down primarily by weak financial performance (TTM $0 revenue, sizeable losses, and ~-$10.0M free cash flow burn). Technicals also remain bearish (price below key moving averages with negative MACD). The only notable offset is a low-debt balance sheet, while valuation signals are limited by negative earnings and no dividend data.

Positive Factors

Revenue Growth

The substantial revenue growth in 2024 indicates a successful market penetration and product acceptance, positioning Kiora for continued expansion in the ophthalmic sector.

Financial Stability

Minimal leverage and a strong equity position provide Kiora with financial flexibility to invest in R&D and withstand market fluctuations, supporting long-term growth.

Profitability

A high gross profit margin reflects efficient cost management and strong pricing power, enhancing Kiora's ability to reinvest in growth initiatives and improve profitability.

Negative Factors

Cash Flow Management

Limited cash flow leverage could restrict Kiora's ability to fund new projects or navigate financial challenges, potentially impacting long-term operational flexibility.

Net Profit Margin

While profitable, the net profit margin suggests room for improving cost controls, which is crucial for sustaining profitability as the company scales operations.

Cash Flow Efficiency

Improving cash flow efficiency is essential for Kiora to enhance liquidity, support strategic investments, and ensure long-term financial health.

Kiora Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

How the Company Makes Money

Kiora Pharmaceuticals generates revenue primarily through the sale and licensing of its ophthalmic products and therapies. The company's revenue model includes direct sales to healthcare providers, partnerships with pharmaceutical companies for the co-development and distribution of its products, and potential milestone payments and royalties from licensing agreements. These partnerships and collaborations are crucial as they provide access to broader markets and additional resources for research and development. Kiora's focus on innovative treatments for eye disorders positions it to capture a niche market, potentially leading to substantial revenue growth as its products gain regulatory approval and market acceptance.

Kiora Pharmaceuticals Financial Statement Overview

Summary

Financial results are high-risk: TTM revenue is $0 with a large net loss (~-$8.5M) and meaningful cash burn (TTM FCF ~-$10.0M). The balance sheet is a relative strength with very low leverage (debt-to-equity ~0.02) and sizable equity (~$22.4M), but it is currently funding losses rather than producing consistent returns.

Income Statement

Profitability has been highly volatile. After a profitable 2024 (about $16.0M revenue and ~$3.6M net income with strong margins), results deteriorated sharply in TTM (Trailing-Twelve-Months) with $0 revenue and a large net loss (~-$8.5M) and negative operating earnings. Earlier years (2020–2023) were also consistently loss-making with minimal/zero revenue, highlighting a business model still heavily dependent on non-recurring income and ongoing R&D spend.

Balance Sheet

Leverage is very low (debt-to-equity ~0.02 in TTM (Trailing-Twelve-Months)), which reduces financial risk and gives flexibility. Equity remains sizable (~$22.4M in TTM (Trailing-Twelve-Months)) and assets are ~$29.9M, but returns have swung from positive in 2024 to deeply negative in TTM (Trailing-Twelve-Months) as losses resumed, indicating the balance sheet is supporting ongoing burn rather than generating consistent shareholder returns.

Cash Flow

Cash generation is currently weak: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both about -$10.0M, reflecting heavy cash burn. While free cash flow improved versus the prior period (positive reported growth), cash flows have been negative in most years outside of 2024 (when operating and free cash flow were strongly positive at ~+$8.6M), suggesting uneven cash conversion and funding needs if burn persists.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	16.00M	0.00	0.00	0.00	12.06K
Gross Profit	-38.23K	16.00M	0.00	0.00	0.00	-3.26M
EBITDA	-7.29M	5.70M	-12.36M	-13.65M	-13.91M	-7.47M
Net Income	-8.54M	3.59M	-12.51M	-13.58M	-13.77M	-6.86M
Balance Sheet
Total Assets	29.86M	36.48M	13.71M	18.68M	20.13M	15.30M
Cash, Cash Equivalents and Short-Term Investments	19.38M	26.79M	2.45M	5.96M	7.85M	1.19M
Total Debt	404.17K	57.17K	106.89K	105.78K	209.41K	574.40K
Total Liabilities	7.45M	10.72M	7.60M	7.27M	5.55M	5.57M
Stockholders Equity	22.41M	25.76M	6.11M	11.41M	14.58M	9.73M
Cash Flow
Free Cash Flow	-10.02M	8.55M	-9.56M	-10.43M	-10.74M	-7.34M
Operating Cash Flow	-10.03M	8.56M	-9.56M	-10.43M	-10.68M	-7.32M
Investing Cash Flow	9.56M	-22.66M	0.00	6.38K	-157.02K	-244.44K
Financing Cash Flow	265.36K	15.50M	5.97M	8.62M	17.58M	5.00M

Kiora Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Positive. The current price of 1.91 is below the 20-day moving average (MA) of 2.17, below the 50-day MA of 2.07, and below the 200-day MA of 2.64, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 67.43 is Neutral, neither overbought nor oversold. The STOCH value of 76.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KPRX.

Kiora Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AEON	54 Neutral	$27.87M	0.23	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNSE	51 Neutral	$11.98M	-0.45	-67.47%	―	―	9.63%
RNAZ	49 Neutral	$8.70M	-0.04	-1763.01%	―	―	96.75%
DWTX	45 Neutral	$89.51M	-0.11	-97.54%	―	―	-295.27%
KPRX	44 Neutral	$8.83M	-0.98	-32.58%	―	-100.00%	-463.97%